TY - JOUR
T1 - Clinical applications of monitoring immune status with 90 immune cell subsets in human whole blood by 10-color flow cytometry
AU - Wang, Weiwei
AU - Li, Haibo
AU - Zhang, Lihua
AU - Jiang, Wenli
AU - Shen, Lisong
AU - Fan, Guang
N1 - Funding Information:
This study was supported by the National Natural Science Foundation of China (81301788) and the Shanghai Youth Medical Talent Training Program for Clinical Laboratory (Shanghai Medicine and Health Development Foundation, HYWJ201605).
Publisher Copyright:
© 2021 John Wiley & Sons Ltd
PY - 2021/10
Y1 - 2021/10
N2 - Introduction: The immune system may involve and predict the different prognosis and therapy consequences. So, it's important to monitor and evaluate the immune status before and after treatments. Methods: Flow cytometry is the best technology to perform immune monitoring, because it can detect immune cells using small amount of sample in a short time. The whole blood is the ideal sample for immune status monitoring, since it includes almost all the immune cells and it's relatively easy to obtain and less invasive than bone marrow or lymph node. Results: Here we developed and validated a 10-color panel with only four tubes containing 29 antibodies to monitor 90 immune cell subsets in 2 ml whole blood samples. The major immune cell populations detected by our panel included T cell subsets (CD3+total T, Th, Tc, Treg, CD8hi, CD8low, αβTCR, γδTCR, naïve, and memory T), T cell activation markers (CD25, CD69, and HLA-DR) and one immune checkpoint PD1, B cell subsets (B1, switched memory, non-switched, naïve B, and CD27-IgD-B cells), neutrophils, basophils, four monocytic cell subsets, dendritic cells (pDCs and mDCs), and four NK cell subsets. These panels of antibodies had been applied to monitor immune status (percentage and absolute number) in total 303 cases with various diseases, such as leukemia (AML, CML, MM, and ALL), lymphoma (B cells and NK/T cells), cancers (colon, lung, prostate, and breast), immune deficiencies, and autoimmune diseases. Conclusion: We provided proof of feasibility for clinical monitoring immune status and guiding immunotherapy by multicolor flow cytometry testing.
AB - Introduction: The immune system may involve and predict the different prognosis and therapy consequences. So, it's important to monitor and evaluate the immune status before and after treatments. Methods: Flow cytometry is the best technology to perform immune monitoring, because it can detect immune cells using small amount of sample in a short time. The whole blood is the ideal sample for immune status monitoring, since it includes almost all the immune cells and it's relatively easy to obtain and less invasive than bone marrow or lymph node. Results: Here we developed and validated a 10-color panel with only four tubes containing 29 antibodies to monitor 90 immune cell subsets in 2 ml whole blood samples. The major immune cell populations detected by our panel included T cell subsets (CD3+total T, Th, Tc, Treg, CD8hi, CD8low, αβTCR, γδTCR, naïve, and memory T), T cell activation markers (CD25, CD69, and HLA-DR) and one immune checkpoint PD1, B cell subsets (B1, switched memory, non-switched, naïve B, and CD27-IgD-B cells), neutrophils, basophils, four monocytic cell subsets, dendritic cells (pDCs and mDCs), and four NK cell subsets. These panels of antibodies had been applied to monitor immune status (percentage and absolute number) in total 303 cases with various diseases, such as leukemia (AML, CML, MM, and ALL), lymphoma (B cells and NK/T cells), cancers (colon, lung, prostate, and breast), immune deficiencies, and autoimmune diseases. Conclusion: We provided proof of feasibility for clinical monitoring immune status and guiding immunotherapy by multicolor flow cytometry testing.
KW - clinical monitoring
KW - human peripheral blood
KW - immune cell subsets
KW - immune status
KW - immunotherapy
KW - multicolor flow cytometry
UR - http://www.scopus.com/inward/record.url?scp=85104406312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104406312&partnerID=8YFLogxK
U2 - 10.1111/ijlh.13541
DO - 10.1111/ijlh.13541
M3 - Article
C2 - 33870648
AN - SCOPUS:85104406312
SN - 1751-5521
VL - 43
SP - 1132
EP - 1144
JO - International Journal of Laboratory Hematology
JF - International Journal of Laboratory Hematology
IS - 5
ER -